Smallpox vaccine - Bavarian Nordic

Drug Profile

Smallpox vaccine - Bavarian Nordic

Alternative Names: IMVAMUNE; IMVAMUNE® liquid-frozen; IMVAMUNE® freeze-dried; IMVANEX; MVA-BN® Smallpox; MVA-BN® smallpox vaccine

Latest Information Update: 14 Mar 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Bavarian Nordic
  • Developer Bavarian Nordic; Centers for Disease Control and Prevention
  • Class Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Smallpox
  • Phase III Monkeypox

Most Recent Events

  • 24 May 2018 Bavarian Nordic announces intention to launch smallpox vaccine in USA in the second half of 2018
  • 28 Feb 2018 Bavarian Nordic completes a phase III trial for Smallpox (Prevention) in South Korea
  • 06 Feb 2018 Bavarian Nordic announces intention to submit BLA to the US FDA for Smallpox (Prevention) in the second half of 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top